ACEi/ARB

ApprovedSmall molecule

Novartis

ACEi/ARB is one of 91 small molecule programs targeting Mortality. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MortalityActive, not recruiting

Ventricular ArrhythmiaActive, not recruiting

ProteinuriaActive, not recruiting

Heart FailureActive, not recruiting

MortalityPreclinical

Active, not recruiting

Ventricular ArrhythmiaApproved

Active, not recruiting

ProteinuriaApproved

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

ACEi/ARB

Novartis

Approved

2 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

LCZ696

Novartis

Preclinical

15 6

Monoferric

PPharmacosmos A/S

Preclinical

5 7

Activase

Roche

Preclinical

—8

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 9

Adriamycin

GGynecologic Oncology Group

Preclinical

—10

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Recruiting

Hypertensive

NCT05498675

Q2 2028

Post-ApprovalRecruiting

Proteinuria

NCT07315191

Clinical

Trials by Indication[1]

Heart Failure2 trials

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Completed· Novartis logo

Novartis··NCT05096143·42,269 enrolled

Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT03821701·340 enrolled

Hypertensive1 trial

Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

Recruiting·—··NCT05498675·180 enrolled

Ventricular arrhythmia1 trial

Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)

Terminated· Novartis logo

Novartis·Phase 4·NCT04491136·201 enrolled

Trial1 trial

Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).

Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 4·NCT05122780·120 enrolled

Mortality1 trial

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

Completed·UUniversity of Utah··NCT04467931·22,213 enrolled

1 more indication

Proteinuria1 trial

Finerenone Therapy for Pediatric HSPN With Mild Proteinuria

Recruiting·—·Phase 4·NCT07315191·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for ACEi/ARB. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACEi/ARB compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACEi/ARB. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

ACEi/ARB

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Trials by Indication[1]

Heart Failure2 trials

Hypertensive1 trial

Ventricular arrhythmia1 trial

Trial1 trial

Mortality1 trial

Proteinuria1 trial

References

Drug Info

Quick Facts

Related News